<DOC>
	<DOCNO>NCT00445679</DOCNO>
	<brief_summary>This study ass safety , tolerability efficacy desvenlafaxine succinate sustain release ( DVS SR ) subject major depressive disorder .</brief_summary>
	<brief_title>Paroxetine-referenced Study Evaluating Three Doses DVS SR Outpatients With MDD</brief_title>
	<detailed_description>The primary objective study investigate efficacy , safety tolerability desvenlafaxine succinate sustain release ( DVS SR ) Chinese , Taiwanese , South Korean , Indian subject major depressive disorder ( MDD ) receive daily dos 50 mg , 100 mg , 200 mg . The secondary objective obtain additional information regard efficacy DVS SR subject MDD receive daily dos 50 mg , 100 mg , 200 mg. Additional objective include obtain general functional quality life outcome data .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Primary 1 . Outpatient men woman least 18 year age . 2 . Have primary diagnosis MDD base criterion Diagnostic Statistical Manual Mental Disorders , 4th edition ( DSM IV ) , single recurrent episode , without psychotic feature . 3 . Have HAM D17 total score â‰¥20 screen baseline ( study day 1 ) visit . Primary 1 . Treatment DVS SR time past . 2 . Significant risk suicide base clinical judgment , include common suicidal thought suicide consider possible solution even without specific plan intent . 3 . Any unstable hepatic , renal , pulmonary , cardiovascular ( include uncontrolled hypertension ) , ophthalmologic , neurologic , medical condition might confound study put subject great risk study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>major depressive disorder</keyword>
	<keyword>MDD</keyword>
	<keyword>depression</keyword>
</DOC>